Cytomedix Appoints Dr. Craig Mendelsohn to
Board of Directors
Gains Industry Veteran with Legal and
Regulatory Affairs Expertise
Rockville, MD. (November
13, 2009) – Cytomedix, Inc. (AMEX:
GTF) a leading developer of biologically active
regenerative therapies for wound care, inflammation and
angiogenesis, today announced the appointment of Craig B.
Mendelsohn, M.D., J.D. to the Company’s Board of Directors,
increasing the number of board members to seven.
Dr. Mendelsohn, age 55, is Vice President and Deputy General
Counsel for the American Red Cross. He brings to Cytomedix
more than 15 years of healthcare industry experience as a
regulatory attorney and medical director in the medical
device and pharmaceutical industries. Dr. Mendelsohn has
significant FDA expertise with a focus on medical device
law, legal affairs and regulatory affairs.
“We are very fortunate that Dr. Mendelsohn has agreed to
join our Board,” said Martin Rosendale, Chief Executive
Officer of Cytomedix. “Dr. Mendelsohn’s impressive track
record and knowledge of the clinical, legal and regulatory
landscape for medical device companies – specifically with
regard to blood and plasma products – will be of tremendous
value to Cytomedix as we build the company into a leading
player in the regenerative medicine field.”
“I am delighted to join Cytomedix at this time of
significant growth and evolution for the Company. Chronic
wounds are a serious health problem worldwide, and I look
forward to working with the Cytomedix team to bring
innovative solutions to these clinical challenges,”
commented Dr. Mendelsohn.
At the American Red Cross, Dr. Mendelsohn is responsible for
managing and leading a staff of attorneys that provide
counsel to the Biomedical Services division at the
organization, while providing guidance and legal counsel to
executive management and the Board of Governors.
Previously, he held senior-level Medical Director and
Regulatory Affairs positions for a number of medical device
and pharmaceutical companies including Cardinal Health, Core
Dynamics and ZLB Bioplasma, as well as at the Plasma Protein
Therapeutics Association. Dr. Mendelsohn began his legal
career in 1994 at the Washington, D.C. headquarters of Hogan
& Hartson, an international full-service law firm, as a
member of the Food, Drug, Agriculture, and Medical Devices
Group. Dr. Mendelsohn also had a private practice in
ophthalmology for ten years prior to obtaining his law
degree.
Dr. Mendelsohn received his Juris Doctor, Cum Laude from
Georgetown University Law Center, his Doctor of Medicine
from George Washington University Medical Center, and his
Bachelor of Arts in Chemistry from Emory University. He is
co-author on a number of papers in both clinical and legal
publications.About Cytomedix
Cytomedix develops, sells
and licenses regenerative biological therapies including the
AutoloGel™ System, a device for the production of Platelet
Rich Plasma ("PRP") gel derived from the patient's own
blood. The AutoloGel™ System is cleared by the U.S. Food and
Drug Administration for use on a variety of exuding wounds.
The Company is pursuing a multi-faceted strategy to
penetrate the chronic wound market with its AutoloGel™
System. The Company is also moving forward with the
development of other product candidates in its pipeline.
Most notably is its CT-112 product, an anti-inflammatory
peptide that has shown promise in preclinical testing.
Additional information regarding Cytomedix is available at
www.cytomedix.com.
About Hair Transplant
Forum International
Hair Transplant Forum
International is a privately published newsletter of the
International Society of Hair Restoration Surgery. Its
contents are solely the opinions of the authors and are not
formally “peer reviewed” before publication. To facilitate
the free exchange of information, a less stringent standard
is employed to evaluate the scientific accuracy of the
letters and articles published in the Forum. The standard of
proof required for letters and articles is not to be
compared with that of formal medical journals. The
newsletter was designed to be and continues to be a printed
forum where specialists and beginners in hair restoration
techniques can exchange thoughts, experiences, opinions, and
pilot studies on all matters relating to hair restoration.
Safe Harbor Statement
Statements contained in
this communication not relating to historical facts are
forward-looking statements that are intended to fall within
the safe harbor rule for such statements under the Private
Securities Litigation Reform Act of 1995. The information
contained in the forward-looking statements is inherently
uncertain, and Cytomedix’s actual results may differ
materially due to a number of factors, many of which are
beyond Cytomedix’s ability to predict or control, including
among others, viability and effectiveness of the Company’s
sales approach and overall marketing strategies, the outcome
of development or regulatory review of CT-112, commercial
success or acceptance by the medical community, competitive
responses, the Company's ability to raise additional capital
and to continue as a going concern, its ability to
successfully commercialize its product in Japan under the
terms of the license agreement, and Cytomedix's ability to
execute on its strategy to market the AutoloGel™ System as
contemplated. These forward-looking statements are subject
to known and unknown risks and uncertainties that could
cause actual events to differ from the forward-looking
statements. More information about some of these risks and
uncertainties may be found in the reports filed with the
Securities and Exchange Commission by Cytomedix, Inc.
Cytomedix operates in a highly competitive and rapidly
changing business and regulatory environment, thus new or
unforeseen risks may arise. Accordingly, investors should
not place any reliance on forward-looking statements as a
prediction of actual results. Except as is expressly
required by the federal securities laws, Cytomedix
undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new
information, changed circumstances or future events or for
any other reason.
|
